Aurinia Pharmaceuticals Inc AUPH

16.44 (0.16) (0.96%) as of 25 Sep
Market cap
$2.2B
P/E
6.9×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
283.06 235.13 175.51 134.03 45.61 50.12 0.32 0.46 0.42 0.17
Revenue Growth
20.38% 33.97% 30.95% 193.89% (9.00%) 15,660.38% (31.32%) 10.77% 141.62% (26.38%)
Cost of Revenue
32.67 28.25 14.15 5.66 1.09 1.08 — — 1.17 1.10
Gross Profit
250.39 206.89 161.37 128.37 44.51 50.12 0.32 0.46 0.42 0.17
R&D Expenses
32.51 20.79 49.64 44.99 51.14 50.33 52.87 41.38 33.93 14.53
SG&A Expenses
101.79 172.03 195.04 196.37 173.54 95.98 22.34 13.67 12.10 6.97
Operating Income
114.44 (9.03) (83.31) (112.99) (180.16) (97.48) (76.02) (56.16) (47.06) (22.81)
Non-operating Income/Expense
(0.29) 16.48 5.84 6.64 (0.04) (5.29) (12.22) (7.89) (23.73) (0.48)
Non-operating Interest Expenses
4.33 4.84 2.78 3.79 0.42 1.19 2.08 1.64 0.83 0.02
EBT
114.16 7.45 (77.47) (106.35) (180.21) (102.77) (88.24) (64.05) (70.79) (23.29)
Income Tax Provision
(173.04) 1.70 0.55 1.83 0.76 (0.09) 0.14 0.07 — —
Income after Tax
287.20 5.75 (78.02) (108.18) (180.97) (102.68) (88.38) (64.12) (70.79) (23.29)
Net Income Common
287.20 5.75 (78.02) (108.18) (180.97) (102.68) (88.38) (64.12) (70.79) (23.29)
EPS (Basic)
2.14 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
EPS (Diluted)
2.07 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
Shares (Basic, Weighted)
134.37 143.06 143.24 141.92 129.37 118.47 93.02 84.78 76.92 35.29
Shares (Diluted, Weighted)
138.70 146.19 143.24 141.92 129.37 118.47 93.02 84.78 76.92 35.29
Gross Margin
88.46% 87.99% 91.94% 95.77% 97.61% 100.00% 100.00% 100.00% 100.00% 100.00%
EBIT Margin
40.43% (3.84%) (47.47%) (84.30%) (395.05%) (194.50%) (23,906.92%) (12,129.16%) (11,259.33%) (13,187.28%)
EBT margin
40.33% 3.17% (44.14%) (79.35%) (395.15%) (205.06%) (27,748.74%) (13,833.05%) (16,935.89%) (13,465.32%)
Net Profit Margin
101.47% 2.45% (44.45%) (80.71%) (396.81%) (204.88%) (27,794.03%) (13,848.81%) (16,935.89%) (13,465.32%)
Free Cash Flow Margin
47.84% 18.76% (19.47%) (59.55%) (346.44%) (150.53%) (20,027.04%) (11,163.07%) (9,855.02%) 7,165.90%
EBITDA
133.89 10.41 (71.66) (110.29) (177.40) (96.11) (74.85) (54.71) (45.73) (21.50)
EBIT
114.44 (9.03) (83.31) (112.99) (180.16) (97.48) (76.02) (56.16) (47.06) (22.81)
Income from Continuous Operations
287.20 5.75 (78.02) (108.18) (180.97) (102.68) (88.38) (64.12) (70.79) (23.29)
Consolidated Net Income/Loss
287.20 5.75 (78.02) (108.18) (180.97) (102.68) (88.38) (64.12) (70.79) (23.29)
EPS (Basic, from Continuous Ops)
2.14 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
EPS (Basic, Consolidated)
2.14 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
EPS (Diluted, from Cont. Ops)
2.07 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
Shares (Diluted, Average)
138.70 146.19 143.24 141.92 129.37 118.47 93.02 84.78 76.95 35.29
EPS (Diluted, Consolidated)
2.07 0.04 (0.54) (0.76) (1.40) (0.87) (0.95) (0.76) (0.92) (0.66)
EBITDA Margin
47.30% 4.43% (40.83%) (82.29%) (388.99%) (191.77%) (23,538.68%) (11,816.63%) (10,939.23%) (12,429.48%)
Operating Cash Flow Margin
47.93% 18.88% (19.06%) (59.34%) (345.78%) (139.39%) (19,995.28%) (11,146.87%) (9,849.04%) (10,816.76%)

Fold the line items

In millions of $ except per-share values · columns are period end dates